ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Pseudomonas aeruginosa (P. aeruginosa).These data were recently presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting held from April 15-18, 2023 in Copenhagen, Denmark.
https://finance.yahoo.com/news/contrafect-data-presentations-33rd-annual-123000430.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.